Literature DB >> 25273865

Wild-type genotypes of BRCA1 gene SNPs combined with micro-RNA over-expression in mammary tissue leading to familial breast cancer with an increased risk of distant metastases' occurrence.

Imen Medimegh1, Wafa Troudi, Nejla Stambouli, Houssein Khodjet-El-Khil, Olfa Baroudi, Hajer Ayari, Ines Omrane, Nancy Uhrhammer, Maud Privat, Amel Mezlini, Farhat Ben Ayed, Khaled Ben Romdhane, Sylvie Mader, Yve Jean Bignon, Amel Benammar Elgaaied.   

Abstract

Germ line deleterious mutations of BRCA1 gene are not the unique factor that could inactivate BRCA1 protein which leads to familial breast cancer onset with distant metastases' occurrence. The present research explores the role that could be assigned to BRCA1 SNPs to inactivate BRCA1 protein and therefore to the occurrence of familial breast cancer with an increased risk of distant metastases' occurrence. The presence or the absence of BRCA1 protein was first analyzed by applying the immunohistochemistry technique to the tumors with sporadic and familial breast cancer. Then, a case-control study was conducted including 40 patients with familial breast cancer, 46 ones with sporadic breast cancer and 34 healthy controls based on the genotyping of nine BRCA1 SNPs (c.442.58delT, c.2082C>T, c.2311T>C, c.2612C>T, c.3113A>G, c.3119G>A, c.3548A>G, c.4308T>C and 4837A>G) via direct sequencing. Finally, the functional role that could be assigned to these SNPs was focused upon. miRbase site was used as a bioinformatics tool to predict potential micro-RNAs (miRs) targeting SNPs that are associated with familial breast cancer according to the results of this research. These predicted miRs were confirmed by Q-PCR analysis and correlated with BRCA1 protein expression among patients along with potential distant metastases. Clinical outcome showed that distant metastasis concerned 45 % of familial breast cancer patients and 19.5 % with sporadic breast cancer. Analysis of BRCA1 protein expression revealed a negative staining among 46.6 % of familial breast cancer patients and only 16.6 % within sporadic breast cancer ones. The association of four variants was identified within BRCA1 gene (c.442.58 delT, c.2311T>C, c.2612C>T and c.4308T>C) to familial breast cancer across their wild genotypes. miR-1179 was selected as potential miR that targets the region of BRCA1 mRNA containing the c.2311T>C variant within the TT genotype. The expression of miR-1179 was significantly associated with familial breast cancer patients without BRCA1 deleterious mutations compared to those with sporadic breast cancer according to TT genotype along with BRCA1 negative staining and according to the occurrence of distant metastases. Combination between TT genotype of c.2311T>C and miR-1179 over-expression could generate a lack of BRCA1 protein leading to a high risk of familial breast cancer with distant metastases.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25273865     DOI: 10.1007/s12032-014-0255-6

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  24 in total

Review 1.  MicroRNAs: small RNAs with a big role in gene regulation.

Authors:  Lin He; Gregory J Hannon
Journal:  Nat Rev Genet       Date:  2004-07       Impact factor: 53.242

2.  Wip1 controls global heterochromatin silencing via ATM/BRCA1-dependent DNA methylation.

Authors:  Doria Filipponi; Julius Muller; Alexander Emelyanov; Dmitry V Bulavin
Journal:  Cancer Cell       Date:  2013-10-14       Impact factor: 31.743

3.  Breast cancer: an increasing public health problem in the Asia Pacific region.

Authors:  Colin Binns; Wah Yun Low; Mi Kyung Lee
Journal:  Asia Pac J Public Health       Date:  2013-09       Impact factor: 1.399

4.  Study of TNFalpha -308G/A and IL6 -174G/C polymorphisms in type 2 diabetes and obesity risk in the Tunisian population.

Authors:  Rym Bouhaha; Thouraya Baroudi; Hajer Ennafaa; Emanuel Vaillant; Hafawa Abid; Rim Sassi; Vincent Vatin; Philippe Froguel; Amel Benammar-el Gaaied; David Meyre; Martine Vaxillaire
Journal:  Clin Biochem       Date:  2010-02-02       Impact factor: 3.281

5.  Tumor suppressor BRCA1 epigenetically controls oncogenic microRNA-155.

Authors:  Suhwan Chang; Rui-Hong Wang; Keiko Akagi; Kyung-Ae Kim; Betty K Martin; Luca Cavallone; Diana C Haines; Mark Basik; Phuong Mai; Elizabeth Poggi; Claudine Isaacs; Lai M Looi; Kein S Mun; Mark H Greene; Stephen W Byers; Soo H Teo; Chu-Xia Deng; Shyam K Sharan
Journal:  Nat Med       Date:  2011-09-25       Impact factor: 53.440

Review 6.  The role of BRCA1 in DNA damage response.

Authors:  Jiaxue Wu; Lin-Yu Lu; Xiaochun Yu
Journal:  Protein Cell       Date:  2010-02       Impact factor: 14.870

7.  MicroRNA expression signature of human sarcomas.

Authors:  S Subramanian; W O Lui; C H Lee; I Espinosa; T O Nielsen; M C Heinrich; C L Corless; A Z Fire; M van de Rijn
Journal:  Oncogene       Date:  2007-10-08       Impact factor: 9.867

8.  BRCA1 germ-line mutations and tumor characteristics in eastern Chinese women with familial breast cancer.

Authors:  Wenming Cao; Xiaojia Wang; Yun Gao; Hongjian Yang; Ji-Cheng Li
Journal:  Anat Rec (Hoboken)       Date:  2012-11-23       Impact factor: 2.064

9.  miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors.

Authors:  Patryk Moskwa; Francesca M Buffa; Yunfeng Pan; Rohit Panchakshari; Ponnari Gottipati; Ruth J Muschel; John Beech; Ritu Kulshrestha; Kotb Abdelmohsen; David M Weinstock; Myriam Gorospe; Adrian L Harris; Thomas Helleday; Dipanjan Chowdhury
Journal:  Mol Cell       Date:  2010-12-30       Impact factor: 17.970

10.  A BRCA1 deficient-like signature is enriched in breast cancer brain metastases and predicts DNA damage-induced poly (ADP-ribose) polymerase inhibitor sensitivity.

Authors:  Ryan P McMullin; Ben S Wittner; Chuanwei Yang; Benjamin R Denton-Schneider; Daniel Hicks; Raj Singavarapu; Sharon Moulis; Jeongeun Lee; Mohammad R Akbari; Steven A Narod; Kenneth D Aldape; Patricia S Steeg; Sridhar Ramaswamy; Dennis C Sgroi
Journal:  Breast Cancer Res       Date:  2014-03-14       Impact factor: 6.466

View more
  2 in total

1.  MicroRNA-1179 inhibits glioblastoma cell proliferation and cell cycle progression via directly targeting E2F transcription factor 5.

Authors:  Xiupeng Xu; Ning Cai; Tongle Zhi; Zhongyuan Bao; Dong Wang; Yinlong Liu; Kuan Jiang; Liang Fan; Jing Ji; Ning Liu
Journal:  Am J Cancer Res       Date:  2017-08-01       Impact factor: 6.166

2.  MicroRNA-1179 regulates proliferation and chemosensitivity of human ovarian cancer cells by targeting the PTEN-mediated PI3K/AKT signaling pathway.

Authors:  Zhang Zhihong; Chen Rubin; Lu Liping; Mao Anpeng; Guo Hui; Wu Yanting; Shan Zhenxiu
Journal:  Arch Med Sci       Date:  2019-07-22       Impact factor: 3.318

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.